AMPA antagonists: do they hold more promise for clinical stroke trials than NMDA antagonists?
The cytoprotective effects of MK-801 and NBQX, selective N-methyl-D-aspartate (NMDA) and alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptor antagonists, respectively, were compared both singularly and in combination in models of transient severe forebrain and transient focal c...
Автори: | Buchan, A, Lesiuk, H, Barnes, K, Li, H, Huang, Z, Smith, K, Xue, D |
---|---|
Формат: | Journal article |
Мова: | English |
Опубліковано: |
1993
|
Схожі ресурси
Схожі ресурси
-
Delayed treatment with AMPA, but not NMDA, antagonists reduces neocortical infarction.
за авторством: Xue, D, та інші
Опубліковано: (1994) -
DELAYED TREATMENT WITH AMPA BUT NOT NMDA GLUTAMATE ANTAGONISTS REDUCES NEOCORTICAL INFARCTION
за авторством: Xue, D, та інші
Опубліковано: (1992) -
POSTISCHEMIC TREATMENT WITH AMPA, BUT NOT NMDA, ANTAGONISTS PREVENTS CA1 NEURONAL INJURY
за авторством: Li, H, та інші
Опубліковано: (1992) -
The rise and fall of NMDA antagonists for ischemic stroke.
за авторством: Hoyte, L, та інші
Опубліковано: (2004) -
NMDA antagonists: their role in neuroprotection.
за авторством: Small, D, та інші
Опубліковано: (1997)